336 Stock Overview
A biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Hepion Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.66 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$0.48 |
| Beta | 1.81 |
| 11 Month Change | -2.24% |
| 3 Month Change | -3.68% |
| 1 Year Change | -77.72% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 336 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | -77.7% | -20.1% | 8.2% |
Return vs Industry: 336 underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 336 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 336 volatility | |
|---|---|
| 336 Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 336's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 336's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 22 | John Brancaccio | hepionpharma.com |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. Fundamentals Summary
| 336 fundamental statistics | |
|---|---|
| Market cap | €3.70m |
| Earnings (TTM) | -€21.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 336 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 336 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.70m |
| Earnings | -US$22.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.92 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -517.8% |
How did 336 perform over the long term?
See historical performance and comparison